Trends in the Incidence, Mortality, and Survival Outcomes of Adult Genital Tumor Patients in the United States from 1975 to 2016

Background: There is no epidemiological study on the trends of the incidence, mortality and survival outcome of adult male and female genital tumors in the US. Methods: The study screened the adult US male and female genital tumors from 1975 to 2016 using the Surveillance, Epidemiology, and End Results database. The entire cohort data were used to evaluate the trends of annual age-adjusted incidence, annual mortality and survival outcomes. The Kaplan-Meier method was used to calculate the survival rate of genital tumors patients. Results: From 1975 to 2016, 979,105 patients were diagnosed with genital tumors, of which 680,903 were male (69.54%). The annual age-adjusted incidence (283.4 per 100,000) and annual mortality (60.0 per 100,000) of male genital tumors have peaked in the 1990s. The annual age-adjusted incidence and annual mortality of female genital tumors showed a downward trend. The incidence of testicular cancer in male increased the fastest during 1975 to 2016, with an average annual increase of 1.2% (APC=1.2). While the incidence of cervical cancer in female decreased the fastest, with an average annual decrease of 2.0% (APC=-2.0). Compared with patients aged 20-50, the incidence and mortality of over 50 years old was significantly higher (p<0.05). The median overall survival (OS) time for male adult genital tumors was 32.6 years, and the median OS time for female genital tumors was 25.8 years. Compared with the grade III and grade IV patients, the grade I and grade II patients had higher survival (p<0.05). Conclusion: The annual age-adjusted incidence and annual mortality of male genital tumors reached peak in the 1990s, and then decreased year by year. The annual age-adjusted incidence and annual mortality of female genital tumors were decreased year by year, and the incidence was reduced by 0.6% annually (APC=-0.6). The survival of all patients has increased significantly. Funding Statement: None. Declaration of Interests: None. Ethics Approval Statement: We signed and submitted the "SEER Research Data Agreement" form via email and obtained permission to access the SEER database.